SCHEMBL2173349

SCHEMBL2173349

CC(C)c1cc(O)c(-c2c(O)cc(C(C)C)cc2C(C)C)c(C(C)C)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 5/20 0.68
GABRB2 P47870 3/20 0.68
FABP3 P05413 2/20 0.48
FABP4 P15090 2/20 0.48
FABP5 Q01469 1/20 0.47
TRPA1 O75762 2/20 0.45
PTGS1 P23219 1/20 0.45
CACNA1C Q13936 1/20 0.45
GABRB1 P18505 3/20 0.43
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
LMNA P02545 4/20 0.40
CHRM1 P11229 1/20 0.40
SLC6A2 P23975 1/20 0.40
ADRA1A P35348 1/20 0.40
HTR2B P41595 1/20 0.40
TYR P14679 2/20 0.39
ALDH1A1 P00352 2/20 0.39
ALOX12 P18054 2/20 0.39
HTT P42858 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1617739 0.81 GABRA1 (1.00) GABRA1GABRB2FABP3FABP4FABP5
SCHEMBL27439431 0.79 GABRA1 (0.65) GABRA1GABRB2FABP3FABP4FABP5
SCHEMBL19972010 0.77 GABRA1 (0.63) GABRA1GABRB2FABP3FABP4FABP5
SCHEMBL94533 0.77 GABRA1 (0.77) GABRA1GABRB2FABP3FABP4FABP5
SCHEMBL4623974 0.76 LMNA (0.56) GABRA1GABRB2TRPA1PTGS1CACNA1C
SCHEMBL9229754 0.76 CA1 (0.64) GABRA1GABRB2FABP3FABP4FABP5
SCHEMBL6294990 0.76 GABRA1 (0.61) GABRA1GABRB2FABP3FABP4FABP5
SCHEMBL29560756 0.76 GABRA1 (0.50) GABRA1GABRB2FABP3FABP4FABP5
SCHEMBL8705685 0.76 GABRA1 (0.50) GABRA1GABRB2FABP3FABP4FABP5
SCHEMBL7715672 0.76 GABRA1 (0.50) GABRA1GABRB2FABP3FABP4FABP5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2346887-B1 SLURRY PROCESS FOR SYNTHESIS OF BISPHOSPHITES DOW TECHNOLOGY INVESTMENTS LLC (US) 2013-12-25 EP disclosed
US-8546600-B2 Slurry process for synthesis of bisphosphites and situ use thereof for producing bisphosphite DOW TECHNOLOGY INVESTMENTS LLC 2013-10-01 US disclosed
US-20110196166-A1 SLURRY PROCESS FOR SYNTHESIS OF BISPHOSPHITES AND SITU USE THEREOF FOR PRODUCING BISPHOSPHITE DOW TECHNOLOGY INVESTMENTS LLC 2011-08-11 US disclosed
EP-2346887-A1 SLURRY PROCESS FOR SYNTHESIS OF BISPHOSPHITES Dow Technology Investments LLC (US) 2011-07-27 EP disclosed
WO-2010042313-A1 SLURRY PROCESS FOR SYNTHESIS OF BISPHOSPHITES DOW TECHNOLOGY INVESTMENTS LLC (US) 2010-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110196166-A1 SLURRY PROCESS FOR SYNTHESIS OF BISPHOSPHITES AND SITU USE THEREOF FOR PRODUCING BISPHOSPHITE SOST, PLCB3, PPIP5K2 GABRA1 3075/4885GABRB2 2406/4885FABP3 1165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.